1. Home
  2. STHO vs IMUX Comparison

STHO vs IMUX Comparison

Compare STHO & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

STHO

Star Holdings Shares of Beneficial Interest

SELL

Current Price

$7.81

Market Cap

120.0M

Sector

Real Estate

ML Signal

SELL

Logo Immunic Inc.

IMUX

Immunic Inc.

SELL

Current Price

$7.94

Market Cap

100.2M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
STHO
IMUX
Founded
2022
2016
Country
United States
United States
Employees
N/A
66
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
120.0M
100.2M
IPO Year
2022
2013

Fundamental Metrics

Financial Performance
Metric
STHO
IMUX
Price
$7.81
$7.94
Analyst Decision
Strong Buy
Analyst Count
0
13
Target Price
N/A
★ $43.09
AVG Volume (30 Days)
38.8K
★ 330.0K
Earning Date
11-17-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
24.73
★ 38.00
EPS
★ 2.58
N/A
Revenue
★ $110,143,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$3.05
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$7.01
$0.51
52 Week High
$9.94
$17.43

Technical Indicators

Market Signals
Indicator
STHO
IMUX
Relative Strength Index (RSI) 43.37 42.34
Support Level $7.76 $6.35
Resistance Level $8.20 $8.60
Average True Range (ATR) 0.25 0.57
MACD 0.07 0.22
Stochastic Oscillator 50.59 61.97

Price Performance

Historical Comparison
STHO
IMUX

About STHO Star Holdings Shares of Beneficial Interest

Star Holdings engages in non-ground lease-related businesses, including real estate finance, operating properties, and land and development. Its portfolio is comprised of its interests in Asbury and Magnolia Green residential development projects, a portfolio of commercial real estate properties, and loans that are being marketed for sale. The Company operates its business through one reportable and operating segment that focuses on realizing value for shareholders by generating cash flows through active asset management and sales of its existing loans, operating properties, and land and development properties.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Share on Social Networks: